Y F Liao1, L L Chen, T S Zeng, J Zheng, H Q Li. 1. Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Abstract
PURPOSE: The aim of this study was to investigate the association between the +33371 A/G polymorphism of adiponectin receptor 2 gene and the risk of Type 2 diabetes (T2DM) in the Chinese population. METHODS: A case-control study was performed among 594 unrelated Chinese people. All of them underwent a standardized assessment on phenotypic characterization including anthropometry, 75-g oral glucose tolerance test with insulin levels, fasting serum total cholesterol, and fasting serum triglyceride. The +33371 A/G polymorphism was detected by PCR-restriction fragment length polymorphism. RESULTS: The PCR products after digestion displayed 3 genotypes, including AA, AG, and GG. The frequencies of AA, AG, and GG genotypes in T2DM group (no.=261) and control group (no.=353) were 0.379, 0.414, 0.207 and 0.162, 0.541, 0.297, respectively. There was a significant difference in both genotypic and allelic frequencies distribution of +33371 A/G polymorphism between T2DM and control subjects (p<0.001). Subjects with AA+AG genotypes showed higher levels of fasting plasma glucose (p=0.024), fasting serum triglycerides (p=0.036), and body mass index (BMI) (p=0.013) than those with GG genotype in the T2DM group but not in the control group. Compared with GG genotype, AA (p<0.001) and AA+AG (p=0.002) genotype group had a significantly higher risk of T2DM, with odds ratio (OR) for 2.290 [95% confidence interval: 1.482-3.359] and 1.963 (1.183-2.997). Compared with AG+GG genotype group, the risk of T2DM in AA genotype increased slightly (p=0.007), with OR for 1.478 (1.025-2.036). CONCLUSION: The present findings suggest that +33371 A/G polymorphism is associated with increased risk of T2DM and multiple insulin resistance-related phenotypes (including fasting plasma glucose, fasting serum triglycerides, and BMI) in the Chinese population.
PURPOSE: The aim of this study was to investigate the association between the +33371 A/G polymorphism of adiponectin receptor 2 gene and the risk of Type 2 diabetes (T2DM) in the Chinese population. METHODS: A case-control study was performed among 594 unrelated Chinese people. All of them underwent a standardized assessment on phenotypic characterization including anthropometry, 75-g oral glucose tolerance test with insulin levels, fasting serum total cholesterol, and fasting serum triglyceride. The +33371 A/G polymorphism was detected by PCR-restriction fragment length polymorphism. RESULTS: The PCR products after digestion displayed 3 genotypes, including AA, AG, and GG. The frequencies of AA, AG, and GG genotypes in T2DM group (no.=261) and control group (no.=353) were 0.379, 0.414, 0.207 and 0.162, 0.541, 0.297, respectively. There was a significant difference in both genotypic and allelic frequencies distribution of +33371 A/G polymorphism between T2DM and control subjects (p<0.001). Subjects with AA+AG genotypes showed higher levels of fasting plasma glucose (p=0.024), fasting serum triglycerides (p=0.036), and body mass index (BMI) (p=0.013) than those with GG genotype in the T2DM group but not in the control group. Compared with GG genotype, AA (p<0.001) and AA+AG (p=0.002) genotype group had a significantly higher risk of T2DM, with odds ratio (OR) for 2.290 [95% confidence interval: 1.482-3.359] and 1.963 (1.183-2.997). Compared with AG+GG genotype group, the risk of T2DM in AA genotype increased slightly (p=0.007), with OR for 1.478 (1.025-2.036). CONCLUSION: The present findings suggest that +33371 A/G polymorphism is associated with increased risk of T2DM and multiple insulin resistance-related phenotypes (including fasting plasma glucose, fasting serum triglycerides, and BMI) in the Chinese population.
Authors: D K Richardson; J Schneider; M J Fourcaudot; L M Rodriguez; R Arya; T D Dyer; L Almasy; J Blangero; M P Stern; R A Defronzo; R Duggirala; C P Jenkinson Journal: Diabetologia Date: 2006-08-29 Impact factor: 10.122
Authors: Coleen M Damcott; Sandra H Ott; Toni I Pollin; Laurie J Reinhart; Jian Wang; Jeffrey R O'connell; Braxton D Mitchell; Alan R Shuldiner Journal: Diabetes Date: 2005-07 Impact factor: 9.461
Authors: A E Civitarese; C P Jenkinson; D Richardson; M Bajaj; K Cusi; S Kashyap; R Berria; R Belfort; R A DeFronzo; L J Mandarino; E Ravussin Journal: Diabetologia Date: 2004-04-23 Impact factor: 10.122
Authors: C Debard; M Laville; V Berbe; E Loizon; C Guillet; B Morio-Liondore; Y Boirie; H Vidal Journal: Diabetologia Date: 2004-05-01 Impact factor: 10.122
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440